Background: Immunotherapy has demonstrated encouraging outcomes in tackling lung adenocarcinoma (LUAD), but immune escape may bring negative impacts. Only a single study has demonstrated the function
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been recommended as the first-line therapy for non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Howe
Table S1. Top mutated genes with predicted HLA Class I binding neo-peptides in 147 lung adenocarcinoma patients in this study. T cell epitopes presented by MHC Class I molecules were predicted by NetM
